An interventional study of Retilut and Theavit in Wet Macular Degeneration, sponsored by Laboratorios Thea, Spain. Completed at 9 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-02-16.
Sponsored by Laboratorios Thea, Spain · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Wet Macular Degeneration with a site in Spain — 4 open to participants now, 5 under way, 5 of them phase 3. Wet Macular Degeneration · Spain.
Among the 14 studies in Wet Macular Degeneration with a site in Spain, this one is the 12th largest by enrollment, is the only one that started in 2014, is the only one with no phase, and was the 2nd registered.
93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.
Browse Wet Macular Degeneration studies →4 of the 14 studies in Wet Macular Degeneration with a site in Spain are open now. Recruiting first, the newest first:
EyeBiotech Ltd. · Sites in Spain, United States, Austria and 10 more countries
Ages 50+
EyeBiotech Ltd. · Sites in Spain, United States, Argentina and 9 more countries
Ages 50+
4D Molecular Therapeutics · Sites in Spain, United States, Argentina and 14 more countries
Ages 50+
King's College Hospital NHS Trust · Sites in Spain, Germany, Ireland and 4 more countries
Ages 50–120
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 8 Wet Macular Degeneration studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 11 · Phase 4 1
First in 2013; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 109 is close to the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.
Median enrollment 609 across the 14 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 10 most frequent:
Laboratorios Thea, Spain is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Laboratorios Thea, Spain has 1 study filed under Wet Macular Degeneration — fewer than ten, so there is no comparison to draw.
1 of the studies in Wet Macular Degeneration with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07064759Phase 34D Molecular TherapeuticsSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Wet Macular Degeneration with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Retinal diseases are currently the leading cause of legal blindness in the developed world. Among these disorders, age-related macular degeneration (AMD) is one of the most prevalent conditions in individuals over 55 years of age. Late AMD, the most severe presentation of the disease, clinically manifests as either geographic atrophy (dry form) or choroidal neovascularization (CNV) (wet form). Although patients with wet AMD only represent 10% of the total cases, CNV is the main and most serious cause of central vision loss. At present, the treatment of wet AMD comprises intraocular injections of certain antiangiogenic agents which act by blocking VEGF (vascular endothelial growth factor). No effective treatment is yet available for dry AMD, though the AREDS (Age-Related Eye Disease Study) has shown that the administration of antioxidant supplements is able to slow progression of the disease. Such vitamin supplements are also indicated in patients who already have severe AMD (both exudative and atrophic) in one eye, since the risk of progression in these cases is high.
Recent studies involving new antioxidant and antiangiogenic molecules such as resveratrol, present in grapes and wine, have also revealed great efficacy in slowing the progression of advanced AMD. Hydroxytyrosol is another polyphenol with important antioxidant and antiinflammatory effects in the RPE.
Considering the above, the present randomized, multicenter interventional study involving Spanish and Portuguese patients with unilateral wet AMD was designed to compare the effects of two different nutritional supplements: one containing the antioxidants and minerals recommended by the AREDS at doses that can be used in the European Union (Theavit), and the other comprising these same substances plus omega-3 fatty acids (lipidic antioxidant), lutein (pigment protecting against light-induced damage) and resveratrol (antioxidant and antiangiogenic agent) (Retilut).
Retinal diseases are currently the leading cause of legal blindness in the developed world. Among these disorders, age-related macular degeneration (AMD) is one of the most prevalent conditions in individuals over 55 years of age. In the United States, the prevalence of AMD varies from 0.5% at 55 years to 7% in people over 75 years. These data are clearly a cause for concern, in view of the aging of the population in developed countries. In Spain, a country with one of the greatest population aging problems, AMD affects 1.7% of all people over 50 years, and the incidence increases with age, reaching 18.5% among those over 85 years. AMD is characterized by progressive destruction of the central region of the retina (macula), resulting in central vision loss. While this does not lead to complete blindness, the associated impairment of autonomy has a very strong impact upon patient quality of life. AMD is a multifactorial disease - a fact that makes it difficult to establish the underlying etiology. In this sense, although only age is accepted as the principal factor associated to the development of AMD, other factors such as smoking, diet, oxidative stress, arterial hypertension or obesity have been extensively investigated in the context of the disease.
Late AMD, the most severe presentation of the disease, clinically manifests as either geographic atrophy (dry form) or choroidal neovascularization (CNV) (wet form). Although patients with wet AMD only represent 10% of the total cases, CNV is the main and most serious cause of central vision loss. At present, the treatment of wet AMD comprises intraocular injections of certain antiangiogenic agents such as ranibizumab, bevacizumab, aflibercept, etc., which act by blocking vascular endothelial growth factor (VEGF). No effective treatment is yet available for dry AMD, though the Age-Related Eye Disease Study (AREDS) has shown that the administration of antioxidant supplements is able to slow progression of the disease. Such vitamin supplements are also indicated in patients who already have severe AMD (both exudative and atrophic) in one eye, since the risk of progression in these cases is high.
The AREDS, sponsored by the National Eye Institute, was started in 1998 with the purpose of evaluating the effect of high-dose antioxidants (vitamins C and E, and beta-carotene) and minerals (zinc) upon the course of the disease. The results of the study showed that high levels of antioxidants and zinc significantly reduced the risk of progression towards advanced stages of AMD by 25%, and of vision loss by 19%. However, due to safety reasons, the doses used in the AREDS cannot be administered in the European Union, since they exceed the Recommended Daily Allowances (RDA). Therefore, the standard clinical practice is to use these substances in patients with high risk AMD as nutritional supplements at the usual RDAs. However, no interventional studies demonstrating the effects of these supplements have been carried out.
Following publication of the AREDS I, certain dietary intake studies suggested the importance of other molecules such as omega-3 fatty acids (DHA, EPA, DPA) and lutein / zeaxanthin. The AREDS work group therefore decided to conduct a new study including both nutrients in addition to those already evaluated (antioxidants and zinc). Lutein exerts an antioxidative effect, can act as a blue light filter, and moreover has antiinflammatory properties. This latter effect is especially important, considering that AMD is a disease secondary to a low-grade chronic inflammatory process of the retinal pigment epithelium (RPE). In addition to their antioxidant and antiinflammatory effects, the omega-3 fatty acids have important antiangiogenic properties, as evidenced both by in vitro and in vivo studies.
Recent studies involving new antioxidant and antiangiogenic molecules such as resveratrol, present in grapes and wine, have also revealed great efficacy in slowing the progression of advanced AMD. Hydroxytyrosol is another polyphenol with important antioxidant and antiinflammatory effects in the RPE.
Considering the above, the present randomized, multicenter interventional study involving Spanish and Portuguese patients with unilateral wet AMD was designed to compare the effects of two different nutritional supplements: one containing the antioxidants and minerals recommended by the AREDS at doses that can be used in the European Union (Theavit), and the other comprising these same substances plus omega-3 fatty acids (lipidic antioxidant), lutein (pigment protecting against light-induced damage) and resveratrol (antioxidant and antiangiogenic agent) (Retilut).
Study Design: A randomized, double-blind, multicenter interventional nutritional dose study was designed. The patient follow-up period will last 24 months. The estimated patient enrollment period will cover 9 months, and analysis of the results will be completed four months after the end of the follow-up period. The estimated total duration of the project will be between 52 months.
Study Subjects:
These patients from the different Spanish populations will be enrolled making use of the infrastructure afforded by the RETICS network, "Eye disease related to aging, vision quality and quality of life" (RD07/0062 subproject Retina). All patients will be 50 years old or more, and written informed consent will be obtained in all cases, together with authorization to enter their data in a database (data protection consent following the criteria of the Ethics Committees of each of the participating centers).
On the baseline visit, the patients will undergo a complete ophthalmological evaluation, and plasma will be collected for posterior analysis of several biochemical parameters.
Those patients who meet the inclusion criteria and none of the exclusion criteria will start nutritional supplementation for two years (2 daily capsule, nutritional dose) with one of the nutritional supplements. The study will be carried out on a simple-blind basis, even the patient knows the origin of the treatment, the ophthalmologist conducting follow-up will not know the composition of the provided supplement. Accordingly, the boxes and capsules will be adequately masked. The blisters with the nutritional supplements will be delivered to each patient at the inclusión visit (Day 0), and the empty blisters are to be returned as an initial measure of treatment compliance. Patient follow-up will take place every 6 months (Day 0, Month 6, Month 12, Month 18, Month 24), and will comprise a complete ophthalmological evaluation, with the registry of any ophthalmological adverse events. The appearance of such adverse events will be a secondary study endpoint, and is defined as the appearance of choroidal neovascularization in the fellow eye. First objective will be the measure of the change in the best corrected visual acuity (BCVA) in the study eye. Blood samples will be collected at Day 0, Month 12 and Month 24 for biochemical analysis (Luminex® markers, omega 3, lutein and zeaxanthin profile and plasma REDOX status) representing also a secondary study endpoints.
Ophthalmological examination:
Biochemical analysis:
The plasma of the patients both on Day 0 and at the end of the study will be subjected to the following determinations:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving Theavit food supplement considered as a placebo treatment for AMD condition. Two capsules/day before breakfast each day for 2 years
Dietary Supplement: Theavit
Patients receiving Retilut food supplement. Two capsules/day before breakfast each day for 2 years
Dietary Supplement: Retilut
antioxidants, antiangiogenic, antiinflammatory micronutrients
antioxidants micronutrients
Also known as: food supplement
Best correct visual acuity (BCVA)
Variation in BCVA in the studied eye.
Time frame: Comparison will be made of best visual acuity recorded in Month 12 versus that recorded on the baseline visit (Day 0).
Best correct visual acuity (BCVA)
Variation in BCVA in the studied eye.
Time frame: Comparison will be made of best visual acuity recorded in Month 24 versus that recorded on the baseline visit (Day 0).
Inflammatory markers
VEGF-A, IL-1 beta, IL-6, IL-8, Eotaxin-2 (CCL24), HGF, PDGF, MCP-1, TNF-alfa and FGF.
Time frame: Determination will be made of the mean values obtained on visits Month 12 with respect to the recorded baseline values on visit Day 0
Lipid blood profile
Biochemical blood profile: Omega-3 lipid profile
Time frame: Determination will be made of the mean values obtained on visits Month 12 with respect to the recorded baseline values on visit Day 0
Lipid blood profile
Biochemical blood profile: Omega-3 lipid profile
Time frame: Determination will be made of the mean values obtained on visits Month 24 with respect to the recorded baseline values on visit Day 0
Carotenoid profile
Biochemical blood profile: lutein and zeaxantine values
Time frame: Determination will be made of the mean values obtained on visits Month 12 with respect to the recorded baseline values on visit Day 0
Carotenoid profile
Biochemical blood profile: lutein and zeaxantine values
Time frame: Determination will be made of the mean values obtained on visits Month 24 with respect to the recorded baseline values on visit Day 0
Adverse Events
Determination and classification of simple and serious adverse events related or not to the study treatment and which appear in the contralateral eye.
Time frame: The percentage of these events will be the cumulative value on visits Month 6 in the study treatment group versus the control group.
Adverse Events
Determination and classification of simple and serious adverse events related or not to the study treatment and which appear in the contralateral eye.
Time frame: The percentage of these events will be the cumulative value on visits Month 12 in the study treatment group versus the control group.
Ran from Nov 2014 to primary completion in Apr 2018, 41 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.